AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
182.96
-1.16 (-0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close184.12
Open184.09
Bid182.41 x 200
Ask182.94 x 100
Day's Range181.29 - 184.82
52 Week Range133.64 - 191.10
Volume3,179,172
Avg. Volume2,512,246
Market Cap133.5B
Beta1.82
PE Ratio (TTM)16.66
EPS (TTM)10.98
Earnings DateOct 25, 2017
Forward Dividend & Yield4.60 (2.51%)
Ex-Dividend Date2017-08-15
1y Target Est190.50
Trade prices are not sourced from all markets
  • "Fast Money" final trades: MU, PYPL and more
    CNBC Videos5 days ago

    "Fast Money" final trades: MU, PYPL and more

    The “Fast Money” traders share their final trades for the day including Micron Technology, PayPal, Goldman Sachs and Amgen.

  • Technician says this one hot sector is about to heat up
    CNBC Videos5 days ago

    Technician says this one hot sector is about to heat up

    Carter Worth, Cornerstone Macro, discusses how the health care sector is starting to heat up. The “Fast Money” traders weigh in.

  • TheStreet.com3 hours ago

    Risk Builds Slowly; Awareness of Risk Suddenly: Best of Kass

    In highlights from this week's trading diary and posts, Kass discusses risk and how it differs from risk awareness.

  • Market Realist2 days ago

    Amgen Stock: Performance in 3Q17

    Amgen stock has risen ~8.2% in 3Q17. It has risen ~25.9% year-to-date as of October 20, 2017.

  • PR Newswire2 days ago

    Amgen Announces Webcast of 2017 Third Quarter Financial Results

    THOUSAND OAKS, Calif., Oct. 20, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 25, 2017, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.

  • What's in the Cards for Amgen (AMGN) this Earnings Season?
    Zacks2 days ago

    What's in the Cards for Amgen (AMGN) this Earnings Season?

    While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
    Zacks5 days ago

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

    Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

  • PR Newswire6 days ago

    Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes

    CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Amgen (AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity. Amgen will leverage its industry-leading expertise in genetic target identification and validation and will have access to Boston Children's Hospital's Division of Pain Medicine to identify patients with abnormal pain conditions.

  • Pharma Industry Outlook - October 2017
    Zacks6 days ago

    Pharma Industry Outlook - October 2017

    Pharma Industry Outlook - October 2017

  • Barrons.com9 days ago

    Can Biotech Stay Healthy Through the End of 2017?

    Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be  focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.

  • PR Newswire10 days ago

    Amgen Foundation Awards Khan Academy $3 Million To Support Development Of Free Comprehensive Biology Lessons

    THOUSAND OAKS, Calif. and MOUNTAIN VIEW, Calif., Oct. 12, 2017 /PRNewswire/ -- The Amgen Foundation today announced a three-year, $3 million grant to Khan Academy to develop comprehensive new biology lessons. The Amgen Foundation is the exclusive sponsor of Khan Academy's biology content. With the Amgen Foundation's support, Khan Academy will create new biology lessons for students and teachers worldwide.

  • Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down
    Investor's Business Daily11 days ago

    Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down

    Dow component Merck said late Wednesday it won't submit applications for approval of a cholesterol drug.

  • Mylan Receives CRL for Neulasta Biosimilar
    GuruFocus.com11 days ago

    Mylan Receives CRL for Neulasta Biosimilar

    Company's co-developer partner has to provide FDA with more data

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks11 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • Amgen Wins Reprieve on Its 2nd-Best-Selling Drug
    Motley Fool12 days ago

    Amgen Wins Reprieve on Its 2nd-Best-Selling Drug

    Biosimilar drugmakers are eager to launch competitors to Amgen's drugs, but one big competitor is going to have to wait a while longer.

  • Forbes12 days ago

    Amgen Puerto Rico Staff Keeping Plant Open Despite Personal Losses From Hurricane Maria

    Continuity efforts at Amgen's Puerto Rico drug manufacturing plant reveal the dedication of the island's workers in the pharmaceutical and medical device industries.

  • Amgen Label Expansion Application for Prolia Accepted by FDA
    Zacks12 days ago

    Amgen Label Expansion Application for Prolia Accepted by FDA

    Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).

  • Market Realist12 days ago

    Tezepelumab Could Help Amgen Develop Its Inflammation Franchise

    According to World Health Organization (or WHO), around 235 million individuals worldwide have asthma.

  • Market Realist12 days ago

    Amgen’s Pipeline Could Boost Its Long-Term Growth Opportunities

    EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.

  • Market Realist12 days ago

    If Approved, Aimovig Could Strengthen Amgen’s Neurology Portfolio

    Aimovig is the only biologic product under investigation that has been designed specifically to prevent a migraine by inhibiting the CGRP (calcitonin gene-related peptide) receptor.

  • PR Newswire13 days ago

    FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis

    THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA, which was submitted on July 28, 2017, is based on a Phase 3 study evaluating Prolia compared with risedronate in patients receiving glucocorticoid treatment. Glucocorticoid medications, which are used to treat many inflammatory conditions, can cause significant side effects, including bone loss.

  • Barrons.com13 days ago

    [$$] Ruling Goes Regeneron's Way

    Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.

  • Market Realist13 days ago

    Biosimilars Could Boost Amgen’s Revenue Growth

    In September 2017, Amgen and Allergan presented results from the Phase 3 trial, which evaluated the safety and efficacy of ABP 980, a proposed biosimilar to Herceptin.

  • Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
    Zacks13 days ago

    Forget Teva (TEVA), Buy These 5 Drug Stocks Instead

    With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.